Device and method for sustained release of antipsychotic medications
A drug delivery device comprising a non-erodible, non-porous housing member defining a reservoir is provided. The reservoir is loaded with a dry formulation of a selected salt of a neuroleptic agent. The housing member has one or more porous partitions, where the pores of the partitions are sufficiently small to retain the insoluble powder particles within the reservoir yet large enough to allow diffusion of the active agent once the device is hydrated. A therapeutic dose of the drug is released from the device at a constant rate over a period of approximately 2-6 months.
1. A drug delivery device, comprising:
a non-erodible, non-porous housing member defining a reservoir, said housing member having first and second opposing ends;
a porous partition positioned in the housing member; and
contained within said reservoir, a drug formulation comprised of a salt form of risperidone selected from the group consisting of risperidone octanoate, risperidone hexanoate and risperidone pentanoate, wherein the drug formulation when hydrated releases risperidone at a rate that provides a therapeutic dose over a period of at least about 2 months.
2. The device according to claim 1 , wherein the therapeutic dose is between about 0.8-2.5 mg/day.
3. The device according to claim 2 , wherein risperidone is released at a substantially zero-order rate of release.
4. The device of claim 1 , wherein the porous partition is positioned in one or both ends of the housing member.
5. The device of claim 1 , wherein the housing member is a cylindrical titanium tube and the porous partition is positioned at both ends of the reservoir.
6. A method for extended delivery of risperidone to a subject in need of treatment, comprising implanting a device according to claim 1 .